Last updated: September 8, 2026
Alpelisib, marketed by Novartis as Piqray and Vijoice, has developed into a commercial product with two distinct markets. Piqray targets adults with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Vijoice targets adults and children aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum, or PROS.
Piqray sales reached approximately $1.1 billion in 2024, up from about $1.0 billion in 2023 and $742 million in 2022. Growth has been supported by biomarker-defined treatment demand, broader molecular testing, and use after endocrine resistance. The main constraints are hyperglycemia, diarrhea, rash, treatment discontinuation, and new competition from inavolisib, approved by the FDA in 2024 for a closely related breast-cancer population. Vijoice provides alpelisib with an orphan-disease growth channel and extends commercial relevance beyond oncology.
What is alpelisib approved to treat?
Alpelisib is an oral, selective phosphatidylinositol-3-kinase alpha, or PI3K-alpha, inhibitor. Its active ingredient is alpelisib, also known as BYL719.
| Brand |
Indication |
FDA status |
Primary commercial market |
| Piqray |
PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer |
Accelerated approval in 2019; regular approval after confirmatory evidence |
Oncology |
| Vijoice |
Severe manifestations of PIK3CA-related overgrowth spectrum |
Approved April 2022 |
Rare disease |
Piqray is administered with fulvestrant after progression on or after an aromatase inhibitor. The FDA indication is limited to tumors with a PIK3CA mutation detected by an FDA-approved test. The pivotal SOLAR-1 trial showed improved progression-free survival in the PIK3CA-mutated population, while the BYLieve study supported activity after CDK4/6 inhibitor exposure, a clinically important treatment setting.[1][2]
Vijoice is administered continuously and has a different commercial profile. It addresses a rare, genetically defined disorder involving abnormal tissue growth, vascular malformations, and other overgrowth manifestations. Unlike Piqray, Vijoice is sold under an orphan-disease framework and is not dependent on metastatic breast-cancer treatment sequencing.[3]
How large is the alpelisib market?
The addressable Piqray market is concentrated in second-line and later-line HR-positive, HER2-negative breast cancer with confirmed PIK3CA mutations.
Approximately 35% to 40% of HR-positive, HER2-negative breast cancers carry a PIK3CA mutation, although the commercially treatable population is smaller because patients must also have advanced disease, prior endocrine therapy, and adequate tolerance for PI3K-alpha inhibition.[1] Molecular testing rates and treatment-line sequencing determine actual demand.
Vijoice has a much smaller patient population but higher orphan-drug economics. PROS is rare, genetically heterogeneous, and often diagnosed through specialist centers. The market is therefore driven by diagnosis, referral, genetic testing, and long-term treatment persistence rather than by broad oncology prescribing volume.
What were Piqray and Vijoice sales?
Novartis reports alpelisib-related sales under Piqray and Vijoice. The approximate trajectory was:
| Year |
Reported sales, approximately |
Market interpretation |
| 2019 |
$80 million |
Partial-year launch |
| 2020 |
$280 million |
Initial oncology uptake |
| 2021 |
$640 million |
Expansion after uptake in PIK3CA-mutated disease |
| 2022 |
$740 million |
Growth tempered by tolerability and treatment sequencing |
| 2023 |
$1.03 billion |
Product passed the $1 billion annual-sales threshold |
| 2024 |
Approximately $1.1 billion |
Continued growth despite competitive pressure |
Sources report sales in company financial disclosures and may reflect currency effects and brand-level aggregation. The overall pattern is clear: alpelisib moved from launch-stage revenue to a mature specialty product with annual sales above $1 billion.[4][5]
What is driving alpelisib revenue growth?
Four factors support alpelisib revenue.
First, PIK3CA testing is becoming more routine in advanced HR-positive, HER2-negative breast cancer. The treatment opportunity depends on identifying eligible patients, making companion-diagnostic penetration a direct commercial driver.
Second, alpelisib is used after endocrine resistance, including after CDK4/6 inhibitor treatment. This expands the relevant treatment population beyond the original SOLAR-1 profile.
Third, Vijoice creates a second indication with longer-duration treatment potential. PROS patients may remain on therapy for extended periods, subject to response, tolerability, and clinical need.
Fourth, the product has an established prescriber base, reimbursement infrastructure, and clinical familiarity. These factors support continued use even as newer PI3K-pathway therapies enter the market.
The main revenue constraints are adverse events. In SOLAR-1, clinically significant hyperglycemia, rash, diarrhea, and dose modification were central management issues. Hyperglycemia can require metformin, endocrinology involvement, monitoring, and treatment interruption. These requirements reduce persistence and can shift physicians toward therapies with a simpler safety profile.[1]
How does alpelisib compare with inavolisib and other competing drugs?
Inavolisib is the most important direct new competitor. Roche’s Genentech developed inavolisib, marketed as Itovebi, for PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib and fulvestrant. The FDA approved inavolisib in October 2024 based on the INAVO120 study.[6]
| Product |
Company |
Target or mechanism |
Key positioning |
Commercial threat to alpelisib |
| Piqray |
Novartis |
PI3K-alpha inhibitor |
Post-endocrine therapy, PIK3CA-mutated disease |
Incumbent standard |
| Itovebi |
Genentech/Roche |
PI3K-alpha inhibitor |
PIK3CA-mutated endocrine-resistant disease with palbociclib and fulvestrant |
High |
| Truqap |
AstraZeneca |
AKT inhibitor |
Biomarker-selected HR-positive, HER2-negative breast cancer |
Moderate |
| Afinitor |
Novartis |
mTOR inhibitor |
Endocrine-resistant breast cancer |
Moderate, established alternative |
| Kisqali and other CDK4/6 inhibitors |
Novartis, Lilly, Pfizer |
CDK4/6 inhibition |
Earlier-line and combination treatment |
Indirect |
Inavolisib may compete effectively where physicians prioritize progression-free survival, combination efficacy, and a potentially more manageable metabolic profile. Piqray retains advantages in market familiarity, single-agent PI3K-alpha specificity, established post-CDK4/6 experience, and broader historical use.
The competitive risk is greatest in newly diagnosed PIK3CA-mutated advanced disease and in practices that rapidly adopt inavolisib-based combinations. The risk is lower in patients already responding to or tolerating Piqray and in the PROS market, where inavolisib has no role.
What is the FDA regulatory status of alpelisib?
Piqray received FDA accelerated approval in May 2019. The indication covered postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on or following an endocrine-based regimen.[7]
The FDA later converted the accelerated approval to regular approval after confirmatory evidence supported clinical benefit. The agency also accepted BYLieve data as relevant evidence for use after CDK4/6 inhibitor and aromatase inhibitor treatment.[2]
Vijoice received FDA approval in April 2022 for adults and pediatric patients aged 2 years and older with severe manifestations of PROS requiring systemic therapy.[3]
Alpelisib therefore has two separate regulatory value drivers:
- A large, competitive oncology indication with biomarker selection.
- A smaller orphan-disease indication with longer treatment duration and less direct competition.
What patents protect alpelisib?
The core alpelisib estate includes composition-of-matter and related pharmaceutical patents owned by Novartis or its affiliates. Public patent records identify U.S. patents covering substituted imidazopyridine compounds, including alpelisib, as well as related formulations and therapeutic uses.
Representative U.S. patents associated with Piqray include:
| Patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 8,415,358 |
Alpelisib chemical genus and related PI3K inhibitors |
Core compound protection |
| U.S. Patent No. 9,018,311 |
Related PI3K inhibitor compounds and use claims |
Supplemental composition protection |
| Orange Book-listed patents |
Product-specific drug substance, formulation, or method claims |
ANDA litigation exposure |
The precise generic-entry date depends on patent-term adjustment, pediatric exclusivity, Orange Book listing status, and the claims asserted in any Paragraph IV litigation. Core U.S. patent protection is expected to extend into the second half of the 2020s, while Vijoice also benefits from orphan-drug exclusivity for the PROS indication.[8][9]
What formulations are protected by alpelisib patents?
Piqray is supplied as oral tablets in 50-mg, 150-mg, and 200-mg strengths. The marketed dosing regimen is 300 mg once daily with food, with dose reduction for toxicity.
Potential formulation barriers include tablet composition, dosage strength, stability, and manufacturing processes. These protections generally have less commercial value than a valid composition-of-matter patent because an ANDA applicant may design around narrower formulation claims. They still increase litigation leverage and can delay approval if listed claims are asserted.
Vijoice is also an oral tablet product but is prescribed in a rare-disease setting where dosage flexibility, pediatric administration, and long-term treatment management may matter more than mass-market manufacturing scale.
When does alpelisib lose exclusivity?
Alpelisib does not have a single exclusivity date applicable to every market.
| Protection |
Expected commercial effect |
| Core composition patents |
Protect the active ingredient against generic substitution until patent expiration or successful invalidation |
| Formulation and method-of-use patents |
Can delay specific ANDA launches if valid and enforceable |
| FDA five-year new chemical entity exclusivity |
Limited relevance because Piqray launched in 2019 and that period has expired |
| Orphan exclusivity for Vijoice |
Protects the PROS indication from approval of the same drug for the same indication during the orphan period |
| Pediatric exclusivity |
May add six months to eligible patents or exclusivity periods if granted |
The first generic-entry scenario is most likely to involve a Paragraph IV ANDA challenging one or more Orange Book patents. A generic entrant could launch before all patents expire if it wins litigation, obtains a settlement permitting an earlier launch, or relies on a noninfringing label that omits protected uses.
Are there Paragraph IV challenges or patent settlements?
No major, publicly disclosed Piqray generic settlement was reported in Novartis’ 2023 or 2024 financial disclosures. The commercial exposure remains tied to the expiration and enforceability of Orange Book-listed patents and to any future ANDA filings.
A Paragraph IV challenge would create three principal risks for Novartis:
- Early generic entry before the expected patent end date.
- Discovery of invalidity or noninfringement during litigation.
- Price erosion if multiple generic manufacturers enter simultaneously.
The risk is lower for Vijoice’s PROS business because orphan-drug exclusivity and the small patient population make generic economics less attractive. The risk remains higher for Piqray because oncology demand is much larger and the product has surpassed $1 billion in annual sales.
What patent litigation affects alpelisib?
The economically material litigation risk is prospective generic litigation rather than reported product-liability or biosimilar litigation. Alpelisib is a small molecule, so biosimilar pathways do not apply. Generic manufacturers would use the ANDA pathway, not the abbreviated biologics pathway.
Patent litigation will likely focus on:
- Core chemical claims covering alpelisib.
- Patent-term adjustment and expiration calculations.
- Salt, polymorph, and crystalline-form claims.
- Tablet formulation claims.
- Method-of-use claims tied to PIK3CA-mutated breast cancer.
- Labeling strategies for indications protected by method patents.
The absence of biosimilar exposure is commercially favorable. The principal loss-of-exclusivity threat is conventional generic substitution after core patent expiry or successful Paragraph IV litigation.
How strong is the alpelisib patent estate?
The estate is commercially meaningful but approaching the period when generic planning becomes active.
Strengths include:
- A validated composition-of-matter position around a marketed small molecule.
- Multiple years of post-launch revenue before expected core patent expiry.
- A companion-diagnostic-linked indication that creates method-of-use value.
- A separate orphan indication for Vijoice.
- High manufacturing and regulatory familiarity that supports lifecycle management.
Weaknesses include:
- Small-molecule generic exposure.
- A safety profile that limits treatment persistence.
- Potential design-around opportunities for formulation claims.
- Increasing competition from inavolisib and other pathway inhibitors.
- A large revenue concentration in one principal oncology product.
The estate is stronger for near-term commercial defense than for long-term exclusivity. Its value depends on preserving the Piqray franchise through the late 2020s and converting Vijoice into a durable rare-disease business.
What generic launch scenarios exist for alpelisib?
Three launch scenarios are commercially relevant.
Scenario 1: Patent-protected delay
Novartis maintains enforceable core claims and generic entry occurs after the principal patent term. Revenue declines gradually before expiry as physicians adopt newer pathway inhibitors.
Scenario 2: Litigation settlement
A generic company receives a licensed entry date before full patent expiry. The settlement protects part of the remaining revenue period but establishes a known erosion date.
Scenario 3: Early at-risk launch
A generic manufacturer launches after an unsuccessful Paragraph IV defense or before final resolution. Price erosion could be rapid, particularly if multiple manufacturers launch within the same period.
Vijoice may experience slower erosion because the PROS market is small, specialist-driven, and protected by orphan exclusivity. Piqray would face the sharper post-exclusivity decline.
What is the revenue outlook for alpelisib?
Alpelisib revenue should remain resilient in the near term but is likely to mature rather than return to its earlier growth rate.
The near-term outlook depends on:
- Continued testing for PIK3CA mutations.
- Uptake after CDK4/6 inhibitor treatment.
- Inavolisib adoption.
- Physician tolerance for hyperglycemia management.
- Vijoice patient identification and treatment persistence.
- The timing of generic entry.
A base-case commercial view is flat-to-moderate growth through the late 2020s, followed by a sharper Piqray decline when generic competition begins. Vijoice can offset part of that decline, but its smaller patient population is unlikely to replace broad oncology revenue on its own.
Novartis has a stronger defense if it uses Vijoice to build a durable rare-disease franchise while preserving Piqray use in later-line patients who are not suitable for competing regimens. The principal downside is rapid displacement by inavolisib before patent expiry.
Key Takeaways
- Alpelisib generated approximately $1.1 billion in 2024 sales across Piqray and Vijoice.
- Piqray remains the primary revenue source and is exposed to competition from inavolisib.
- Vijoice adds an orphan-disease market with less direct competitive pressure.
- Hyperglycemia, rash, diarrhea, and dose modification constrain Piqray persistence.
- Alpelisib is a small molecule and faces generic, not biosimilar, competition.
- Core patent protection is expected to extend into the latter half of the 2020s, subject to patent-term and litigation outcomes.
- No major publicly disclosed Piqray generic settlement was reported in Novartis’ cited financial disclosures.
- The franchise has strong near-term protection but limited long-term insulation from generic erosion.
FAQs
Is alpelisib a biologic or a small-molecule drug?
Alpelisib is an orally administered small-molecule PI3K-alpha inhibitor. Generic manufacturers would use the ANDA pathway, and biosimilar rules do not apply.
Does Vijoice have separate patent protection from Piqray?
Vijoice relies on the same active ingredient but benefits from separate regulatory positioning for PROS. Its commercial protection also includes orphan-drug exclusivity for the approved indication.
Is alpelisib used before or after CDK4/6 inhibitors?
Piqray is primarily used after endocrine resistance and can be prescribed after exposure to a CDK4/6 inhibitor. Treatment sequencing depends on prior therapy, mutation status, disease burden, and tolerability.
What diagnostic is required before prescribing Piqray?
Patients must have a PIK3CA mutation identified by an FDA-approved diagnostic test. Testing can be performed on tumor tissue or, where appropriate, plasma-derived circulating tumor DNA.
Which company is most likely to challenge alpelisib commercially?
Genentech is the most significant branded competitor through inavolisib. Generic manufacturers represent the larger long-term threat after relevant patents and regulatory exclusivities expire.
References
-
André, F., Ciruelos, E., Rubovszky, G., et al. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.
-
Rugo, H. S., André, F., Yamashita, T., et al. (2021). Time course and management of key adverse events during alpelisib plus fulvestrant in PIK3CA-mutated advanced breast cancer. Annals of Oncology, 32(12), 1531-1540.
-
U.S. Food and Drug Administration. (2022). FDA approves alpelisib for PIK3CA-related overgrowth spectrum. FDA.
-
Novartis AG. (2023). 2023 annual report. Basel, Switzerland: Novartis.
-
Novartis AG. (2024). 2024 annual report. Basel, Switzerland: Novartis.
-
U.S. Food and Drug Administration. (2024). FDA approves inavolisib with palbociclib and fulvestrant for PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. FDA.
-
U.S. Food and Drug Administration. (2019). FDA approves alpelisib for metastatic breast cancer. FDA.
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. Patent Nos. 8,415,358 and 9,018,311. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
